Drug news
NICE questions cost benefit of Lemtrada- Genzyme/Sanofi
In an appraisal of Lemtrada (alemtuzumab), the National Institute for Health and Care Excellence (NICE) raised questions to determine whether Lemtrada offers the NHS a positive cost benefit balance. NICE has requested Genzyme/Sanofi to provide "a series of clarifications on the evidence submitted", and the company has until January 9 to provide this information.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.